MEDA Pharma GmbH & Co. KG

A look at financing, M&A, and alliance activity October-December 2007 In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking—for October-Decem

A look at financing, M&A, and alliance activity July-–September 2007 In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking—for July–September

Spec pharma has created significant value in the US, but not, so far, in Europe. Still, Europe’s spec pharma hopefuls aren’t giving up, and they’re trying out variations on the theme—some starting wit

Born of a leveraged buy-out, MedPointe is subject to financial restraints that demand focus on earnings. Beyond competing with far bigger pharma marketers, management's key challenge remains bringing